CTXR250516P1000
- 0.20
- 0.000.00%
Citius Pharmaceuticals Newsroom
H.C. Wainwright Maintains Citius Pharmaceuticals(CTXR.US) With Buy Rating, Maintains Target Price $4
H.C. Wainwright Maintains Citius Pharmaceuticals(CTXR.US) With Buy Rating, Cuts Target Price to $4
Citius Pharmaceuticals Analyst Ratings
Citius Pharmaceuticals Is Maintained at Buy by D. Boral Capital
Citius Pharmaceuticals Price Target Maintained With a $9.00/Share by D. Boral Capital
D. Boral Capital Upgrades Citius Pharmaceuticals(CTXR.US) to Buy Rating, Announces Target Price $9
Citius Pharma Analyst Ratings
D. Boral Capital Upgrades Citius Pharma to Buy, Announces $9 Price Target
Maxim Group Maintains Citius Pharmaceuticals(CTXR.US) With Buy Rating
Promising Outlook for Citius Pharmaceuticals: Buy Rating Affirmed Amid Product Potential and Strategic Developments
D. Boral Capital Downgrades Citius Pharmaceuticals(CTXR.US) to Hold Rating
Citius Pharmaceuticals Cut to Hold From Buy by D. Boral Capital
Citius Pharma Analyst Ratings
Maxim Group Maintains Citius Pharmaceuticals(CTXR.US) With Buy Rating, Maintains Target Price $4
Citius Pharmaceuticals' Lymphir and Keytruda Combo Shows Promising Clinical Outcomes, Earning a Buy Rating
H.C. Wainwright Maintains Citius Pharmaceuticals(CTXR.US) With Buy Rating, Maintains Target Price $4
Citius Pharmaceuticals Price Target Maintained With a $4.00/Share by HC Wainwright & Co.
Citius Pharma Analyst Ratings
Citius Pharma Analyst Ratings
Maxim Group Maintains Citius Pharmaceuticals(CTXR.US) With Buy Rating, Maintains Target Price $4